HIV infection and osteoporosis: Pathophysiology, diagnosis, and treatment options

Current Osteoporosis Reports

Volumn 10, Issue 4, 2012, Pages 270-277

  Rothman, Micol S ^a   Bessesen, Mary T ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Bone density; Fracture; HAART; HIVinfection; Osteoporosis

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ALENDRONIC ACID; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CALCIUM; COLECALCIFEROL; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; INTERLEUKIN 6; LAMIVUDINE; LOPINAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VITAMIN D; ZIDOVUDINE; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; CAUSAL ATTRIBUTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY CONSERVATION AGENTS; HIV INFECTIONS; HUMANS; INCIDENCE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PREVALENCE; RISK FACTORS;

EID: 84872191999     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-012-0125-0     Document Type: Article

References (37)

1. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146(2):87-95. (Pubitemid 351640011)
2. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-801. doi:10.1093/ infdis/jir188.
3. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical infectious diseases : An official publication of the Infectious Diseases Society of America. 2010;51(8):963-72. doi:10.1086/ 656417.
4. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS. 2006;20(17):2165-74. doi:10.1097/QAD.0b013e32801022eb. (Pubitemid 44684707)
5. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: Prevalence and associated factors . AIDS. 2008;22(3):395-402. doi:10.1097/ QAD.0b013e3282f423dd.
6. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clinical infectious diseases : An official publication of the Infectious Diseases Society of America. 2010;51(8):937-46. doi:10.1086/656412.
7. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93(9):3499-504. doi:10.1210/jc.2008-0828.
8. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6(2): E17217. doi:10.1371/journal.pone.0017217.
9. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS. 2009;23(8):1021-4. doi:10.1097/QAD.0b013e3283292195.
10. Ofotokun I, McIntosh E, Weitzmann MN. HIV: Inflammation and bone. Curr HIVAIDS Rep. 2012;9(1):16-25. doi:10.1007/s11904-011-0099-z.
11. Pacifici R. The immune system and bone. Arch Biochem Biophys. 2010;503(1):41-53. doi:10.1016/j.abb.2010.05.027.
12. Rifas L, Weitzmann MN. A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum. 2009;60 (11):3324-35. doi:10.1002/art.24877.
13. Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A. 2010;107(31):13848-53. doi:10.1073/pnas.1003020107.
14. Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: Risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes. 2010;17(6):523-9. doi:10.1097/ MED.0b013e32833f48d6.
15. Brown TT, Ross AC, Storer N, Labbato D, McComsey GA. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: Tenofovir versus non-tenofovir regimens. Antivir Ther. 2011;16(7):1063-72. doi:10.3851/IMP1874.
16. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23(12):1519-29. doi:10.1097/QAD.0b013e32832c1792.
17. Arora S, Agrawal M, Sun L, Duffoo F, Zaidi M, Iqbal J. HIV and bone loss. Curr Osteoporos Rep. 2010;8(4):219-26. doi:10.1007/ s11914-010-0036-x.
18. Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6(8):e23688. doi:10.1371/ journal.pone.0023688.
19. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med. 2012. doi:10.1056/NEJMoa1110711.
20. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15(3):425-9. doi:10.3851/ IMP1502.
21. Gibellini D, Borderi M, de Crignis E, Clo A, Miserocchi A, Viale P, et al. Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line. The new microbiologica. 2010;33(2):109-15.
22. Santiago F, Oguma J, Brown AM, Laurence J. Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir. Biochem Biophys Res Commun. 2012;417(1):223-30. doi:10.1016/j.bbrc.2011.11.089.
23. Yin MT, Modarresi R, Shane E, Santiago F, Ferris DC, McMahon DJ, et al. Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women. Osteoporosis international : A journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2011;22(5):1459-68. doi:10.1007/ s00198-010-1363-6.
24. Foca E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, et al. Prospective evaluation of bone markers, parathormone and 1,25-(OH)(2) vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis. 2012;12:38. doi:10.1186/1471-2334-12-38.
25. Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, Larrousse M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012;26 (4):475-81. doi:10.1097/QAD. 0b013e32834f3507.
26. Piso RJ, Rothen M, Rothen JP, Stahl M. Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr. 2011;56 (4):320-4. doi:10.1097/QAI. 0b013e31820cf010.
27. Yin MT, Zhang CA, McMahon DJ, Ferris DC, Irani D, Colon I, et al. Higher rates of bone loss in postmenopausal HIV-infected women: A longitudinal study. J Clin Endocrinol Metab. 2012;97 (2):554-62. doi:10.1210/jc.2011-2197.
28. Pacifici R. Role of T cells in ovariectomy induced bone loss-revisited. J Bone Miner Res. 2012;27(2):231-9. doi:10.1002/ jbmr.1500.
29. Dickinson SA, Fantry LE. Use of Dual-Energy X-Ray Absorptiometry (DXA) Scans in HIV-Infected Patients. J Int Assoc Phys AIDS Care (Chic). 2012. doi:10.1177/1545109712438751.
30. Lari M, Parsa N, Marzban M, Shams M, Faramarzi H. Depression, Testosterone Concentration, Sexual Dysfunction and Methadone Use Among Men with Hypogonadism and HIV Infection. AIDS Behav. 2012;on line June 22 2012.
31. Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazzi C, et al. Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One. 2011;6(12):e28512. doi:10.1371/journal.pone.0028512.
32. Pepe J, Isidori AM, Falciano M, Iaiani G, Salotti A, Diacinti D, et al. The Combination Of Frax And Aging Male Symptoms Scale Better Identifies Treated Hiv Males At Risk For Major Fracture. Clin Endocrinol. 2012. doi:10.1111/j.1365-2265.2012.04452.x.
33. Longenecker CT, Hileman CO, Carman TL, Ross AC, Seydafkan S, Brown TT, et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: A randomized placebo-controlled trial. Antivir Ther. 2012;17(4):613-21. doi:10.3851/IMP1983.
34. Cotter AG, Mallon PW. Therapeutic options for low bone mineral density in HIV-infected subjects. Curr HIV AIDS Rep. 2012;9 (2):148-59. doi:10.1007/s11904-012-0117-9.
35. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: A randomized controlled trial. J Clin Endocrinol Metab. 2007;92(4):1283-8. doi:10.1210/jc.2006-2216. (Pubitemid 46556399)
36. Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men. J Clin Endocrinol Metab. 2012;97(6):1922-8. doi:10.1210/jc.2012-1424.
37. Huang J, Meixner L, Fernandez S, McCutchan JA. A doubleblinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23 (1):51-7. doi:10.1097/QAD.0b013e32831c8adc.